VIDEO: Most-favored nation pricing: Updates and strategic insights from Tim Wright, Genesis Research Group

Most-favored nation (MFN) pricing proposes linking US drug prices to those paid in selected international reference markets, creating significant uncertainty for manufacturers as policymakers consider multiple implementation pathways. At ISPOR Europe 2025, Tim Wright (Executive Vice President, Access & Pricing, Genesis Research Group) assessed MFN’s legal and structural constraints and outlined practical steps manufacturers can take to prepare under uncertainty, offering timely guidance for pricing, market access and HEOR professionals.

In this follow-up, Wright reflects on the latest developments in the MFN debate, its interaction with the recently announced second round of Medicare drug price negotiations under the Inflation Reduction Act and what manufacturers can expect in the months ahead.

Video contents:

• Overview of the recent ISPOR Europe 2025 session (MFN Pricing: ‘More Fun to Navigate’ – A European Roadmap to Success)
• The GENEROUS Model in relation to MFN
• The differences between MFN and the IRA, and how and where they might intersect
• Advice and practical steps to prepare for MFN activities

Speaker

Tim Wright
Executive Vice President, Access and Pricing, Genesis Research Group

Tim Wright leads the Access & Pricing division at Genesis Research Group. An economist and health economist, Tim has 30 years of experience in the biopharma sector, including 18 years in executive positions in strategic consulting firms and 12 years in global EU and UK roles in industry. In consulting, Tim has provided strategic leadership in over 1000 engagements with small biotechs to top-five pharma and across all therapy areas. Within the industry, Tim was responsible for global pricing and access strategy for two mega-brands and the CV, respiratory, infection and inflammation early asset portfolio at AstraZeneca. He is former Head of HEOR at Janssen Cilag UK, and brings experience from EU Pricing for Allergan and his time as a clinical scientist at Astra.

The views and opinions expressed in this feature are those of the interviewee and do not necessarily reflect the views or positions of Genesis Research Group and its affiliates. The information provided is for general information purposes only and should not be taken as professional advice.

The opinions expressed in this feature are those of the author and do not necessarily reflect the views of The Evidence Base® or Becaris Publishing Ltd.

Sponsorship for this Video was provided by Genesis Research Group.